27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer's Disease (AD) is a pathology with increasing prevalence in the context of a more long-lived society and it is the first cause of dementia in western countries. 2 key findings →
Design: systematic review Participants: 12,458 Evidence: high
Full summary, score breakdown and related studies → Original source
Data collection and analysis We initially screened search results using a 'crowdsourcing' method in which members of Cochrane's citizen science platform identify RCTs. 4 key findings →
Design: meta-analysis Participants: 400 Evidence: high
Full summary, score breakdown and related studies → Original source
Dementia is a common medical condition in the ageing population, and cognitive intervention is a non-pharmacologic strategy to improve cognitive functions. 1 key finding →
Design: meta-analysis Participants: 1,489 Evidence: high
Full summary, score breakdown and related studies → Original source
Our results highlight the need for adequate isolation and protective measures. 5 key findings →
Design: meta-analysis Participants: 135 Evidence: high
Full summary, score breakdown and related studies → Original source
Exercise interventions were performed 3.4 ± 1.4 days per week at moderate intensity (3.7 ± 0.6 metabolic equivalents) for 45.2 ± 17.0 minutes per session for 18.6 ± 10.0 weeks and consisted primarily of aerobic exercise (65%). 5 key findings →
Design: meta-analysis Participants: 1,145 Evidence: high
Full summary, score breakdown and related studies → Original source
Only RCTs were included in this study; there were eleven studies ( n = 2609 participants) of the Mediterranean diet, seven studies ( n = 313) of the ketogenic diet and one study ( n = 37) of the MIND diet. 4 key findings →
Design: systematic review Participants: 2,609 Evidence: high
Full summary, score breakdown and related studies → Original source
This systematic review suggests that CCT interventions could improve global cognitive function in patients with MCI. 5 key findings →
Design: systematic review Participants: 1,059 Evidence: high
Full summary, score breakdown and related studies → Original source
28 studies (total n = 1337 participants, average age 79-90 years) were included in the systematic review, of which 21 could be meta-analyzed. 4 key findings →
Design: systematic review Participants: 1,337 Evidence: high
Full summary, score breakdown and related studies → Original source
We found no data on our primary outcome of global cognitive function. 5 key findings →
Design: meta-analysis Participants: 1,183 Evidence: high
Full summary, score breakdown and related studies → Original source
The Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet seems a promising approach to preserve brain function during aging. 4 key findings →
Design: systematic review Participants: 40 Evidence: high
Full summary, score breakdown and related studies → Original source
We found no studies on our primary outcome of global cognitive function. 5 key findings →
Design: meta-analysis Participants: 1,183 Evidence: high
Full summary, score breakdown and related studies → Original source
Two reviewers independently screened the search results and reference lists of the identified papers and related reviews. 5 key findings →
Design: meta-analysis Participants: 18 Evidence: high
Full summary, score breakdown and related studies → Original source
Few nutritional interventions were found to convincingly improve cognition of individuals with MCI. 5 key findings →
Design: systematic review Participants: 500 Evidence: high
Full summary, score breakdown and related studies → Original source
This meta-analysis provides evidence that CCT improves cognitive function in older people with MCI. 2 key findings →
Design: systematic review Participants: 690 Evidence: high
Full summary, score breakdown and related studies → Original source
Our findings suggest that higher adherence to the MIND diet was associated with better cognitive function and potentially slower cognitive decline in later life. 4 key findings →
Design: meta-analysis Participants: 4,066 Evidence: high
Full summary, score breakdown and related studies → Original source
The included studies (n=15) assessed change in cognition in response to a multidomain lifestyle intervention. 5 key findings →
Design: systematic review Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source
Dementia prevalence is a global public health concern. 2 key findings →
Design: systematic review Participants: 17 Evidence: high
Full summary, score breakdown and related studies → Original source
Our study confirmed the effectiveness of psychosocial interventions for improving cognition or slowing down the progression of cognitive impairment in AD patients and recommended several interventions for clinical practice. 3 key findings →
Design: meta-analysis Participants: 682 Evidence: high
Full summary, score breakdown and related studies → Original source
This review suggests the advantage of combined interventions over exercise with comparable effects when compared with cognitive interventions in the population with mild cognitive impairment and dementia. 4 key findings →
Design: meta-analysis Participants: 2,910 Evidence: high
Full summary, score breakdown and related studies → Original source
Adherence to the MeDi diet may reduce the risk of MCI and AD. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Cognitive impairment is a central non-motor symptom of Parkinson's disease (PD), and there are no established treatments. 4 key findings →
Design: meta-analysis Participants: 679 Evidence: high
Full summary, score breakdown and related studies → Original source
Hippocampal volume is a marker of brain health and is reduced with aging and neurological disease. 4 key findings →
Design: meta-analysis Participants: 23 Evidence: high
Full summary, score breakdown and related studies → Original source
Based on the current evidence, rTMS was an effective therapy for cognitive impairment in AD. 5 key findings →
Design: meta-analysis Participants: 240 Evidence: high
Full summary, score breakdown and related studies → Original source
Given projected increases in dementia prevalence, emphasising earlier stages of cognitive impairment in older adults enables targeted early intervention strategies. 2 key findings →
Design: meta-analysis Participants: 4,120 Evidence: high
Full summary, score breakdown and related studies → Original source
The heterogeneous and multi-factorial nature of dementia requires the consideration of all health aspects when predicting the risk of its development and planning strategies for its prevention. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →